The development of generics that combines "DPP-4 Inhibitors" and "SGLT-2 Inhibitors," which are not covered so far, is underway. This is because there are less than two years left until the end of the PMS, which can be approved for generics. Until now, the domestic market for DPP4+SGLT2 complex has not been formed due to benefit issues, but generic companies are also paying attention as benefit issues are recently being discussed.

GC Pharma received approval from the MFDS on the 25th for the biological equivalence test plan of GC2123A. The active ingredients are known as Empagliflozin+Linagliptin.

Empagliflozin+Linaglipin are the active ingredients of Esglito, which was approved by Bering